MX2022001647A - Terapia de combinacion con vildagliptina y metformina. - Google Patents
Terapia de combinacion con vildagliptina y metformina.Info
- Publication number
- MX2022001647A MX2022001647A MX2022001647A MX2022001647A MX2022001647A MX 2022001647 A MX2022001647 A MX 2022001647A MX 2022001647 A MX2022001647 A MX 2022001647A MX 2022001647 A MX2022001647 A MX 2022001647A MX 2022001647 A MX2022001647 A MX 2022001647A
- Authority
- MX
- Mexico
- Prior art keywords
- metformin
- pharmaceutically acceptable
- acceptable salt
- vildagliptin
- combination therapy
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003105 metformin Drugs 0.000 title abstract 4
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 title abstract 4
- 229960001254 vildagliptin Drugs 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a un inhibidor de DPP-IV (preferentemente vildagliptina o una sal farmacéuticamente aceptable de la misma) y metformina o una sal farmacéuticamente aceptable de la misma, para su uso en el tratamiento de la diabetes tipo 2. La invención también se refiere al uso de un inhibidor de DPP-IV (preferentemente vildagliptina o una sal farmacéuticamente aceptable de la misma) y metformina o una sal farmacéuticamente aceptable de la misma, en la fabricación de un medicamento para tratar la diabetes tipo 2. La invención también se refiere a un método para tratar la diabetes tipo 2 usando un inhibidor de DPP-IV (preferentemente vildagliptina o una sal farmacéuticamente aceptable de la misma) y metformina o una sal farmacéuticamente aceptable de la misma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901645P | 2019-09-17 | 2019-09-17 | |
| US202063004230P | 2020-04-02 | 2020-04-02 | |
| PCT/EP2020/075993 WO2021053076A1 (en) | 2019-09-17 | 2020-09-17 | Combination therapy with vildagliptin and metformin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001647A true MX2022001647A (es) | 2022-03-11 |
Family
ID=72561784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001647A MX2022001647A (es) | 2019-09-17 | 2020-09-17 | Terapia de combinacion con vildagliptina y metformina. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11103469B2 (es) |
| EP (2) | EP4335438A1 (es) |
| JP (1) | JP2022548214A (es) |
| KR (1) | KR20220063157A (es) |
| BR (1) | BR112022003183A2 (es) |
| MA (1) | MA55763A (es) |
| MX (1) | MX2022001647A (es) |
| WO (1) | WO2021053076A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4335438A1 (en) * | 2019-09-17 | 2024-03-13 | Novartis AG | Combination therapy with vildagliptin and metformin |
| KR20230163635A (ko) | 2022-05-24 | 2023-12-01 | 주식회사 엘지에너지솔루션 | 심플 배터리팩 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| BRPI0107715B8 (pt) | 2000-01-21 | 2021-05-25 | Novartis Ag | produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv |
| KR20130105741A (ko) | 2003-11-17 | 2013-09-25 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| US7935723B2 (en) | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
| KR20070068407A (ko) | 2004-10-25 | 2007-06-29 | 노파르티스 아게 | Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물 |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP4335438A1 (en) * | 2019-09-17 | 2024-03-13 | Novartis AG | Combination therapy with vildagliptin and metformin |
-
2020
- 2020-09-17 EP EP23206468.3A patent/EP4335438A1/en active Pending
- 2020-09-17 JP JP2022514973A patent/JP2022548214A/ja active Pending
- 2020-09-17 MA MA055763A patent/MA55763A/fr unknown
- 2020-09-17 US US17/023,539 patent/US11103469B2/en active Active
- 2020-09-17 BR BR112022003183A patent/BR112022003183A2/pt unknown
- 2020-09-17 EP EP20775259.3A patent/EP3958857A1/en not_active Withdrawn
- 2020-09-17 WO PCT/EP2020/075993 patent/WO2021053076A1/en unknown
- 2020-09-17 MX MX2022001647A patent/MX2022001647A/es unknown
- 2020-09-17 KR KR1020227005192A patent/KR20220063157A/ko unknown
-
2021
- 2021-07-26 US US17/385,008 patent/US12090125B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3958857A1 (en) | 2022-03-02 |
| WO2021053076A1 (en) | 2021-03-25 |
| US20220184006A1 (en) | 2022-06-16 |
| EP4335438A1 (en) | 2024-03-13 |
| US11103469B2 (en) | 2021-08-31 |
| US20210077430A1 (en) | 2021-03-18 |
| MA55763A (fr) | 2022-04-20 |
| BR112022003183A2 (pt) | 2022-05-17 |
| JP2022548214A (ja) | 2022-11-17 |
| US12090125B2 (en) | 2024-09-17 |
| KR20220063157A (ko) | 2022-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008453A (es) | Metodos de tratamiento para el abuso de sustancias. | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MY170728A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
| NZ603319A (en) | Diabetes therapy | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2021007477A (es) | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. | |
| MX2018013729A (es) | Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. | |
| MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
| MX2022005388A (es) | Compuestos de pirrolidina y piperidina. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| MX2023008016A (es) | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. | |
| MX2022011475A (es) | Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus. | |
| MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2021011610A (es) | Combinaciones de iadademstat para terapia contra el cancer. |